A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology ...

Intraperitoneal (IP) chemotherapy has theoretical, pharmacologic, and clinical advantages over intravenous (IV) chemotherapy in women with optimally debulked epithelial ovarian cancer confined to the ...

A study featured in this month's edition of Gynecologic Oncology examines the challenges associated with the administration of intra-abdominal chemotherapy, also known as intraperitoneal (IP) ...

Ovarian cancer is the fifth leading cause of cancer death among women, with more cancer deaths than any other malignancy of the female genital system. 1, 2 The 5-year survival of patients with ...